Relapse Multiple Myeloma Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Relapse Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Elranatamab in R/R Multiple Myeloma

Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Massachusetts General Hospital32 enrolled3 locationsNCT06138275
Recruiting
Phase 2

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

Refractory Multiple MyelomaRelapse Multiple Myeloma
Janssen Research & Development, LLC130 enrolled38 locationsNCT06500884
Recruiting
Not Applicable

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

Relapse Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT07359014
Recruiting
Phase 1

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin31 enrolled1 locationNCT07093554
Recruiting
Phase 2

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Multiple MyelomaRelapse Multiple Myeloma
University of Chicago83 enrolled1 locationNCT05789303
Recruiting
Phase 1

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
David Avigan25 enrolled2 locationsNCT06799026
Recruiting
Phase 2

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

Refractory Multiple MyelomaRelapse Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled13 locationsNCT06171685
Recruiting
Phase 3

Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

Multiple MyelomaRelapse Multiple Myeloma
Assistance Publique - Hôpitaux de Paris318 enrolled1 locationNCT06561854
Recruiting
Phase 1Phase 2

Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

Multiple MyelomaRelapse Multiple Myeloma
Sheba Medical Center75 enrolled1 locationNCT05243212